Gamma Delta T Cell Expansion Using TGF-Beta
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding γδ T-cells, particularly Vγ9Vδ2 T-cells, for cancer immunotherapy are inefficient and result in limited clinical efficacy, as they fail to produce high yields of effector cells with enhanced anti-tumor activity.
Innovation Solution
Culturing isolated activated peripheral blood mononuclear cells (PBMCs) in a medium containing transforming growth factor-beta (TGF-β) under specific conditions, which favors the production of effector γδ T-cells with therapeutic activity against malignant diseases, while avoiding the production of regulatory T-cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to expand γδ T-cells, then the expansion process is simple, but the yield of effector cells is low and clinical efficacy is limited
Solution Approach 1:
The patent applies parameter changes by modifying the culture medium composition, specifically adding TGF-β at controlled concentrations (0.1-100 ng/ml) and adjusting cytokine combinations (IL-2, IL-15, IL-21) to optimize effector cell differentiation. This chemical parameter modification transforms the expansion protocol from producing regulatory cells to producing therapeutic effector cells with enhanced anti-tumor activity.
Solution Approach 2:
TGF-β serves as an intermediary substance in the patent that mediates the differentiation of γδ T-cells from a regulatory phenotype to an effector phenotype. By introducing this intermediate cytokine into the culture system, the patent enables controlled production of therapeutic cells without requiring complex multi-step protocols.
2Productivity
If TGF-β is added to the culture medium, then the yield and efficacy of effector T-cells is enhanced, but the risk of producing regulatory T-cells with immunosuppressive function increases
Solution Approach 1:
The patent applies local quality by creating specific micro-environment conditions in the culture system where TGF-β is present at optimized concentrations (0.1-100 ng/ml) combined with specific cytokine ratios (IL-2, IL-15, IL-21). These localized quality parameters ensure that TGF-β promotes effector cell differentiation rather than regulatory cell formation, as the harmful effect only occurs at suboptimal or excessive concentrations.
Solution Approach 2:
The patent employs feedback mechanisms by monitoring and adjusting TGF-β concentration and cytokine supplementation during the expansion process. The protocol includes controlled addition of cytokines at specific time points based on cell proliferation rates, creating a feedback loop that prevents regulatory T-cell formation while maintaining high effector cell yields.
3Productivity
If high concentrations of cytokines are used to enhance cell expansion, then the expansion efficiency increases, but the cost and potential toxicity increase
Solution Approach 1:
The patent applies partial action by using optimized, moderate concentrations of cytokines rather than high doses. Specifically, TGF-β is used at 0.1-100 ng/ml and cytokines are added at controlled intervals rather than continuously at high concentrations. This partial action approach achieves sufficient expansion efficiency while minimizing cost and reducing toxicity risks associated with excessive cytokine dosing.
Data Source
AI summary
A method for expanding a population of γδ T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-β) under conditions in which the production of effector γδ T-cells having therapeutic activity against malignant disease is favored. The use of TGF-β in the production of effector cells in particular Vγ9Vδ2 T-cells is also described and claimed.